- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-1-1-mer
- Ligands
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.8: 10 residues within 4Å:- Chain C: E.213, P.214, V.256, L.263, N.264, G.380, C.445, V.446, S.447
- Ligands: NAG.38
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:G.380, C:V.446
NAG-NAG-BMA-MAN-MAN.11: 10 residues within 4Å:- Chain E: E.213, L.263, N.264, F.377, C.379, G.380, C.445, V.446, S.447
- Ligands: NAG.57
3 PLIP interactions:3 interactions with chain E- Hydrophobic interactions: E:V.446
- Hydrogen bonds: E:G.380, E:V.446
- 54 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.13: 6 residues within 4Å:- Chain A: N.90
- Chain B: G.16, T.18, N.114, T.116, Q.119
Ligand excluded by PLIPNAG.14: 6 residues within 4Å:- Chain A: N.236, T.238, S.276, E.277, N.278, I.279
Ligand excluded by PLIPNAG.15: 1 residues within 4Å:- Chain A: N.243
Ligand excluded by PLIPNAG.16: 2 residues within 4Å:- Chain A: N.278, T.280
Ligand excluded by PLIPNAG.17: 3 residues within 4Å:- Chain A: S.389, G.390, N.393
Ligand excluded by PLIPNAG.18: 2 residues within 4Å:- Chain A: N.340, W.396
Ligand excluded by PLIPNAG.19: 4 residues within 4Å:- Chain A: N.297, V.334, S.335, R.444
Ligand excluded by PLIPNAG.20: 4 residues within 4Å:- Chain A: N.264, S.293, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.2
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain A: N.303, I.324, V.442
Ligand excluded by PLIPNAG.22: 4 residues within 4Å:- Chain A: Q.132, S.152, F.153, N.154
Ligand excluded by PLIPNAG.23: 3 residues within 4Å:- Chain A: R.194, N.199
- Chain E: R.310
Ligand excluded by PLIPNAG.24: 1 residues within 4Å:- Chain A: N.135
Ligand excluded by PLIPNAG.25: 1 residues within 4Å:- Chain A: N.356
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: E.269, E.270, N.291
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain A: N.139, G.325
Ligand excluded by PLIPNAG.28: 5 residues within 4Å:- Chain A: N.364, S.365, N.387
- Ligands: NAG-NAG.1, NAG-NAG.1
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain B: N.107, S.109, E.110
Ligand excluded by PLIPNAG.30: 1 residues within 4Å:- Chain B: N.126
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain C: E.89, N.90
- Chain D: G.16, S.17
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain C: N.236, G.237, S.276
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain C: D.232, T.242, N.243
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain C: N.278, T.280, N.281
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain C: N.387, S.389
- Ligands: NAG.45
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain C: N.340
Ligand excluded by PLIPNAG.37: 5 residues within 4Å:- Chain C: Q.295, N.297, N.333, S.335, R.444
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain C: N.264, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN.8
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain C: N.303, I.324
Ligand excluded by PLIPNAG.40: 4 residues within 4Å:- Chain C: Q.132, S.152, F.153, N.154
Ligand excluded by PLIPNAG.41: 5 residues within 4Å:- Chain A: R.310
- Chain C: V.176, R.194, N.199, T.200
Ligand excluded by PLIPNAG.42: 1 residues within 4Å:- Chain C: N.135
Ligand excluded by PLIPNAG.43: 1 residues within 4Å:- Chain C: N.356
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain C: E.270, N.291, E.292
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain C: N.364, S.365, N.387
- Ligands: NAG.35
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain D: N.107, S.109, E.110
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain D: N.126, Y.127
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain D: N.100, T.102
Ligand excluded by PLIPNAG.49: 4 residues within 4Å:- Chain E: E.89, N.90
- Chain F: G.16, S.17
Ligand excluded by PLIPNAG.50: 4 residues within 4Å:- Chain E: N.236, T.238, S.276, I.279
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain E: D.232, T.242, N.243
Ligand excluded by PLIPNAG.52: 2 residues within 4Å:- Chain E: N.278, N.281
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain E: G.390, N.393
- Ligands: NAG-NAG.10
Ligand excluded by PLIPNAG.54: 1 residues within 4Å:- Chain E: N.340
Ligand excluded by PLIPNAG.55: 5 residues within 4Å:- Chain E: N.297, T.299, H.331, N.333, R.444
Ligand excluded by PLIPNAG.56: 4 residues within 4Å:- Chain E: Q.295, N.297, N.333, S.335
Ligand excluded by PLIPNAG.57: 4 residues within 4Å:- Chain E: N.264, S.293, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN.11
Ligand excluded by PLIPNAG.58: 3 residues within 4Å:- Chain E: N.303, I.324, V.442
Ligand excluded by PLIPNAG.59: 4 residues within 4Å:- Chain E: Q.132, S.152, F.153, N.154
Ligand excluded by PLIPNAG.60: 4 residues within 4Å:- Chain C: R.310
- Chain E: R.194, N.199, T.200
Ligand excluded by PLIPNAG.61: 3 residues within 4Å:- Chain E: N.135, T.137, K.149
Ligand excluded by PLIPNAG.62: 2 residues within 4Å:- Chain E: K.352, N.356
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain E: E.269, N.291, K.345
Ligand excluded by PLIPNAG.64: 5 residues within 4Å:- Chain E: N.364, S.365, S.366
- Ligands: NAG-NAG.10, NAG-NAG.10
Ligand excluded by PLIPNAG.65: 2 residues within 4Å:- Chain F: S.125, N.126
Ligand excluded by PLIPNAG.66: 2 residues within 4Å:- Chain F: N.100, T.102
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Antanasijevic, A. et al., Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat Commun (2021)
- Release Date
- 2021-08-04
- Peptides
- BG505 SOSIP.v5.2 N241/N289 - gp120: ACE
BG505 SOSIP.v5.2 N241/N289 - gp41: BDF
Rh.33311 pAbC-1 - Heavy Chain: G
Rh.33311 pAbC-1 - Light Chain: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
EB
BD
DF
FG
HH
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-1-1-mer
- Ligands
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 54 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Antanasijevic, A. et al., Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat Commun (2021)
- Release Date
- 2021-08-04
- Peptides
- BG505 SOSIP.v5.2 N241/N289 - gp120: ACE
BG505 SOSIP.v5.2 N241/N289 - gp41: BDF
Rh.33311 pAbC-1 - Heavy Chain: G
Rh.33311 pAbC-1 - Light Chain: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
EB
BD
DF
FG
HH
L